Loading, Please Wait...

CST: 19/11/2019 08:05:38   

Avadel Pharmaceuticals Reports First Quarter 2019 Financial Results

195 Days ago

  • REST-ON 63% enrolled; 98 patients remain to be enrolled
     
  • Jordon Dubow, M.D., appointed as Chief Medical Officer
     
  • Noctiva™-related assets sold; all operational activities have ceased

DUBLIN, Ireland, May 08, 2019 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on developing FT218 for sleep disorders, today announced its financial results for the first quarter of 2019 and provided an update on its transformational progress.

“We have made substantial progress on restructuring the company, since our announcement in February to make development of FT218 the core focus of the company,” said Greg Divis, Interim Chief Executive Officer. “FT218 is a novel, once nightly therapy being studied for the treatment of excessive daytime sleepiness and cataplexy in patients suffering from narcolepsy. In keeping with our commitment to deliver on the promise of FT218, we recently hired Jordon Dubow, M.D., as our Chief Medical Officer. Dr. Dubow brings many years of relevant neurology experience, including in sleep, to Avadel and his insight will be invaluable as we continue to advance FT218."

Dr. Dubow added, “Having had the opportunity to review findings from the third-party diagnostic of the REST-ON clinical trial and the FT218 development program more broadly, I am confident in the status of the program overall and in our ability to complete trial enrollment in the second half of 2020. I believe that FT218 is a highly promising product candidate with clear differentiation over standard-of-care in a large addressable market and could provide significant clinical benefit to patients suffering from narcolepsy.”

First quarter and recent company highlights

  • The REST-ON clinical trial has enrolled 166 patients, which is 63% of the target enrollment; 98 patients remain to be enrolled; based on current trends, enrollment is expected to be completed in the second half of 2020;
     
  • The Company has been issued new intellectual property covering FT218’s novel once nightly formulation; the patent issued from the U.S. Patent and Trademark Office has an expiry date in 2037;
     
  • Jordan Dubow, M.D., was appointed Chief Medical Officer; Dr. Dubow will lead the development of FT218;
     
  • The assets of Avadel Specialty Pharmaceuticals, LLC, a subsidiary solely responsible for the sales, marketing and distribution of Noctiva™, have been sold; there are no Noctiva-related personnel or activities remaining at the Company;
     
  • Restructuring actions already completed will result in $50 to $60 million of annual cost savings; actions underway, and expected to conclude before December 31, 2019, are expected to realize the full $80-$90 million of cost reductions previously announced; and
     
  • Revenues of $16.4 million in the first quarter of 2019 exceeded the top of end of the Company’s previous guidance of $13 to $15 million; annual revenue is now expected to exceed $30 million (vs. the prior expectation of annual revenue possibly below $30 million).

Overview of first quarter 2019 financial results:

Revenues for the first quarter of 2019 were $16.4 million, compared to $33.3 million in the first quarter of 2018. The decline on a year-over-year basis was primarily attributed to lower net selling prices across all of the Company’s hospital products as a result of increased market competition. Revenue for the first quarter of 2019 exceeded the top end of the guided range provided in March of $13 to $15 million.

  Three Months Ended March 31,
 Revenues by Product: ($ in 000s) 2019   2018
       
Bloxiverz $ 2,568     $ 7,491  
Vazculep 9,473     12,961  
Akovaz 3,792     10,217  
Other (1) 604     2,492  
Total product sales 16,437     33,161  
License revenue -     132  
Total revenues $ 16,437     $ 33,293  
  1. Noctiva revenue included in “Other”; Noctiva revenue for the three months ended March 31, 2019 represents revenue earned from January 1, 2019 through February 5, 2019, prior to the deconsolidation of Avadel Specialty Pharmaceuticals, LLC.

Research and development (R&D) expense was $7.3 million in the first quarter of 2019 compared to $10.0 million in the first quarter of 2018. This decline was a result of $1.3 million of lower spending associated with the exit of Noctiva and $1.2 million of cost reductions at the company’s Lyon, France R&D center. The company continues to invest a substantial portion of R&D in its FT218 development program.

Selling, general and administrative (SG&A) expense was $10.4 million in the first quarter of 2019 compared to $24.5 million for the first quarter of 2018. This decrease is a result of a decline in sales and marketing costs of $10.1 million associated with exit of Noctiva and costs of $2.7 million in the first quarter of 2018 that did not recur in the first quarter of 2019 due to the February 2018 disposition of the company’s pediatric products.

Net loss for the first quarter of 2019 was $13.0 million or $0.35 per share compared to a net loss of $12.2 million or $0.32 per share for the same period in 2018.  Included in the net loss in the first quarter of 2019 was a loss on the deconsolidation of Avadel Specialty Pharmaceuticals, LLC of $2.7 million.  As a result of Avadel Specialty Pharmaceuticals, LLC bankruptcy filing on February 6, 2019, the company concluded that it no longer controls the operations of this subsidiary and accordingly deconsolidated this subsidiary.

Cash, cash equivalents and marketable securities were $79.9 million as of March 31, 2019, compared to $99.9 million as of December 31, 2018.  Based on our current FT218 clinical development plan, anticipated cost structure and hospital products revenue projections, cash is anticipated to be sufficient to fund operations into 2021. The company has convertible debt of $144 million due in 2023.

2019 Guidance:

Based on recent hospital products sales performance and continuing to factor in increased competition from products launched, expected to be launched in 2019, and possible market price actions, which have not yet occurred, hospital product revenue for 2019 is now expected to exceed $30 million. The Company submitted an NDA to the U.S. Food and Drug Administration (FDA) in March of 2019 on a fourth Hospital Product, AV001, which, if approved, could contribute revenues to Avadel in 2020.

Conference Call:

A conference call to discuss these results has been scheduled for Wednesday, May 8, 2019 at 8:30 a.m. EDT. A question and answer period will follow management's prepared remarks. To access the conference call, investors are invited to dial (844) 388-0559 (U.S. and Canada) or (216) 562-0393 (International). The conference ID number is 3258059. A live audio webcast can be accessed by visiting the investor relations section of the Company’s website, www.avadel.com. A replay of the webcast will be archived on Avadel’s website for 90 days following the event.

About Avadel Pharmaceuticals plc:

Avadel Pharmaceuticals plc (Nasdaq: AVDL) is a branded specialty pharmaceutical company.  The Company’s primary focus is on the development and potential FDA approval for FT218, which is in a Phase 3 clinical trial for the treatment of narcolepsy patients suffering from excessive daytime sleepiness (EDS) and cataplexy.  In addition, Avadel markets three sterile injectable drugs used in the hospital setting, which were developed under the Company’s “unapproved marketed drug” (UMD) program.  Avadel is headquartered in Dublin, Ireland with operations in St. Louis, Missouri and Lyon, France. For more information, please visit www.avadel.com.

Cautionary Disclosure Regarding Forward-Looking Statements

This press release includes “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These forward-looking statements relate to our future expectations, beliefs, plans, strategies, objectives, results, conditions, financial performance, prospects, or other events. In some cases, forward-looking statements can be identified by the use of words such as “will,” “may,” “believe,” “expect,” “guidance,” “anticipate,” “estimate,” “project” and similar expressions, and the negatives thereof (if applicable).

Our forward-looking statements are based on estimates and assumptions that are made within the bounds of our knowledge of our business and operations and that we consider reasonable.  However, our business and operations are subject to significant risks and as a result there can be no assurance that actual results of our research, development and commercialization activities and the results of our business and operations will not differ materially from the results contemplated in such forward-looking statements.  Factors that could cause actual results to differ from expectations in our forward-looking statements include:

(a) risks relating to our 2018 net loss and recent restructuring plan, including risks relating to the following:

  • due to a decrease in our available liquid assets, our business strategy has been refocused and is now substantially dependent upon a single product, FT218;

  • our recent restructuring plan may not be as effective as we anticipate and may have unintended negative impacts;

  • further restructuring actions, if needed, may require third-party consents that may not be granted;

  • the Chapter 11 bankruptcy filing by our subsidiary Avadel Specialty Pharmaceuticals LLC may have unexpected adverse results; and

  • a management-directed third-party evaluation of our FT218 development program could result in changes that increase the cost of the program and further delay its completion;

(b) risks relating to the following:

  • our three products Bloxiverz®, Vazculep® and Akovaz®, which are not patent protected, and have a small number of customers, produce a majority of our revenues, and could face further competition resulting in a further loss of market share and/or forcing us to further reduce our prices for those products;

  • our current “unapproved marketed drug” (UMD) product candidate, AV001, could fail to achieve FDA approval; or we could fail to develop future potential UMD product candidates, or competitors could develop such products and market such products with FDA approval before us;

  • we could experience failure or further delay in completing the Phase III clinical trial for FT218, and if the FDA ultimately approves such product, the approval may not include any period of market exclusivity;

  • we may not have sufficient cash or the ability to raise sufficient cash to service our $143.75 million Exchangeable Senior Notes due 2023, including cash necessary to repay such Notes at maturity, to settle exchanges of such Notes in cash or to repurchase such Notes as required following a “fundamental change” event described in the indenture governing such Notes;

  • our products may not reach the commercial market or gain market acceptance;

  • we must invest substantial sums in research and development in order to remain competitive;

  • we depend on one or a limited number of providers to develop certain of our products and drug delivery technologies, to manufacture certain of our products and to provide certain raw materials used in our products;

  • our competitors may develop and market technologies or products that are more effective or safer than ours, or obtain regulatory approval and market such technologies or products before we do;

  • we face challenges in protecting intellectual property underlying our products and drug delivery technologies; and

  • we depend on key personnel to execute our business plan.

(c) the other risks and uncertainties described in the “Risk Factors” section of Part I, Item 1A of our Annual Report on Form 10-K for the year ended December 31, 2018 which we filed with the Securities and Exchange Commission on March 15, 2019.

Forward-looking statements speak only as of the date they are made and are not guarantees of future performance.  Accordingly, you should not place undue reliance on forward-looking statements.  We do not undertake any obligation to publicly update or revise the forward-looking statements contained in this Annual Report.

Contacts: Michael F. Kanan
  Chief Financial Officer
  Phone: (636) 449-1844
  Email: mkanan@avadel.com
   
  Alex Gray
  Burns McClellan
  Phone: (212) 213-0006
  Email: agray@burnsmc.com

AVADEL PHARMACEUTICALS PLC

UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF LOSS

(In thousands, except per share data)

(Unaudited)

    Three Months Ended March 31,
    2019   2018
         
Revenues:        
Product sales   $ 16,437     $ 33,161  
License revenue       132  
Total revenues   16,437     33,293  
Operating expenses:        
Cost of products   3,266     6,592  
Research and development expenses   7,329     9,951  
Selling, general and administrative expenses   10,446     24,487  
Intangible asset amortization   201     1,767  
Gain - changes in fair value of related party contingent consideration   2,134     2,968  
Restructuring costs   1,228     153  
Total operating expenses   24,604     45,918  
Operating loss   (8,167 )   (12,625 )
Investment and other income, net   817     54  
Interest expense   (3,062 )   (1,597 )
Loss on deconsolidation of subsidiary   (2,673 )    
Other income - changes in fair value of related party payable   (307 )   (395 )
Loss before income taxes   (13,392 )   (14,563 )
Income tax benefit   (374 )   (2,327 )
Net loss   $ (13,018 )   $ (12,236 )
         
Net loss per share - basic   $ (0.35 )   $ (0.32 )
Net loss per share - diluted   (0.35 )   (0.32 )
         
Weighted average number of shares outstanding - basic   37,354     38,559  
Weighted average number of shares outstanding - diluted   37,354     38,559  
             

AVADEL PHARMACEUTICALS PLC

UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS

(In thousands, except per share data)

    March 31, 2019   December 31, 2018
    (unaudited)    
ASSETS        
Current assets:        
Cash and cash equivalents   $ 9,630     $ 9,325  
Marketable securities   70,221     90,590  
Accounts receivable   11,772     11,330  
Inventories   4,258     4,770  
Prepaid expenses and other current assets   6,556     8,836  
Total current assets   102,437     124,851  
Property and equipment, net   1,749     1,911  
Operating lease right-of-use assets   5,802      
Goodwill   18,491     18,491  
Intangible assets, net   1,428     1,629  
Research and development tax credit receivable   7,591     7,272  
Other non-current assets   36,124     36,146  
Total assets   $ 173,622     $ 190,300  
         
LIABILITIES AND SHAREHOLDERS’ (DEFICIT) EQUITY        
Current liabilities:        
Current portion of long-term debt   $ 104     $ 106  
Current portion of long-term related party payable   9,391     9,439  
Current portion of operating lease liability   982      
Accounts payable   4,150     3,503  
Deferred revenue   115     114  
Accrued expenses   14,689     21,695  
Other current liabilities   1,927     3,526  
Total current liabilities   31,358     38,383  
Long-term debt, less current portion   117,178     115,734  
Long-term related party payable, less current portion   18,202     19,401  
Long-term operating lease liability   3,889      
Other non-current liabilities   12,577     14,002  
Total liabilities   183,204     187,520  
         
Shareholders’ (deficit) equity:        
Preferred shares, nominal value of $0.01 per share; 50,000 shares authorized; none issued or outstanding at March 31, 2019 and December 31, 2018, respectively        
Ordinary shares, nominal value of $0.01 per share; 500,000 shares authorized; 42,762 issued and 37,355 outstanding at March 31, 2019 and 42,720 issued and 37,313 outstanding at December 31, 2018   427     427  
Treasury shares, at cost, 5,407 shares held at March 31, 2019 and December 31, 2018, respectively   (49,998 )   (49,998 )
Additional paid-in capital   434,199     433,756  
Accumulated deficit   (371,007 )   (357,989 )
Accumulated other comprehensive loss   (23,203 )   (23,416 )
Total shareholders’ (deficit) equity   (9,582 )   2,780  
Total liabilities and shareholders’ (deficit) equity   $ 173,622     $ 190,300  
                 

AVADEL PHARMACEUTICALS PLC

UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(In thousands, Unaudited)

    Three Months Ended March 31,
    2019   2018
         
Cash flows from operating activities:        
Net loss   $ (13,018 )   $ (12,236 )
Adjustments to reconcile net loss to net cash provided by operating activities:        
Depreciation and amortization   369     1,985  
Amortization of premiums on marketable securities   9     518  
Remeasurement of related party acquisition-related contingent consideration   2,134     2,968  
Remeasurement of related party financing-related contingent consideration   307     395  
Amortization of debt discount and debt issuance costs   1,445     657  
Change in deferred tax and income tax deferred charge   (222 )   (2,851 )
Stock-based compensation expense   351     2,134  
Loss on deconsolidation of subsidiary   1,750      
Other adjustments   (550 )   139  
Net changes in assets and liabilities        
Accounts receivable   (1,021 )   (1,891 )
Inventories   467     (466 )
Prepaid expenses and other current assets   (3,228 )   (2,285 )
Research and development tax credit receivable   (449 )   (494 )
Accounts payable & other current liabilities   752     6,374  
Accrued expenses   (4,750 )   (5,854 )
Accrued income taxes   (46 )   32  
Earn-out payments for related party contingent consideration in excess of acquisition-date fair value   (3,181 )   (5,790 )
Royalty payments for related party payable in excess of original fair value   (507 )   (825 )
Other assets and liabilities   (1,818 )   (518 )
Net cash used in operating activities   (21,206 )   (18,008 )
         
Cash flows from investing activities:        
Purchases of property and equipment   (30 )   (41 )
Proceeds from sales of marketable securities   34,864     194,400  
Purchases of marketable securities   (13,444 )   (275,098 )
Net cash provided by (used in) investing activities   21,390     (80,739 )
         
Cash flows from financing activities:        
Earn-out payments for related party contingent consideration       (402 )
Proceeds from debt issuance       143,750  
Payments for debt issuance costs       (5,391 )
Share repurchases       (18,000 )
Proceeds from the exercise of warrants       2,911  
Other financing activities, net   92     47  
Net cash provided by financing activities   92     122,915  
         
Effect of foreign currency exchange rate changes on cash and cash equivalents   29     179  
         
Net change in cash and cash equivalents   305     24,347  
Cash and cash equivalents at January 1,   9,325     16,564  
Cash and cash equivalents at March 31,   $ 9,630     $ 40,911  

 

Is your business listed correctly on America’s largest city directory network of 1,000 portals?